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Objectives: To assess the prevalence and genotypes of Ambler class A extended-spectrum b-lactamases
(ESBLs) in Korea.
Methods: Clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 12 Korean hos-
pitals during February–July 2003 were evaluated. Antimicrobial susceptibilities were determined by disc
diffusion and agar dilution methods, and the putative ESBL-producing strains were tested by the
double-disc synergy method. Detection of genes encoding class A b-lactamases was performed by
PCR amplification, and the PCR products were subjected to direct sequencing.
Results:The double-disc synergy test showedpositive results in 9.3% (23/246) ofE. coli and 23.0% (55/239)
of K. pneumoniae isolates. The most prevalent types of Ambler class A ESBLs in E. coli isolates were
CTX-M-15 (n=4) andCTX-M-3 (n=3), and those inK.pneumoniae isolateswereSHV-12 (n=30) andCTX-M-3
(n = 13). Two isolates produced both SHV-12 and GES-3, simultaneously.
Conclusions: CTX-M-type and/or SHV-12 ESBL-producing E. coli and K. pneumoniae isolates are
spreading, and a GES-type ESBL has emerged in Korea.
Keywords: ESBLs, resistance, prevalence
Introduction
Escherichia coli and Klebsiella pneumoniae are the most frequent
bacteria that produce SHV- and TEM-type extended-spectrum
b-lactamases (ESBLs) and SHV-2a, SHV-12 and TME-52 are
common in Korea.1 CTX-M-type ESBLs, the most widely spread
enzymes among non-TEM and non-SHV plasmid-mediated
ESBLs, were initially reported in the late 1980s in Europe.2 At
present, the CTX-M family comprises more than 40 enzymes that
have similar substrate specificities and inhibitor profiles to TEM
and SHV derivatives but show greater hydrolytic activity against
cefotaxime than ceftazidime. In Korea, CTX-M-3-, CTX-M-14-
and CTX-M-15-producing E. coli and K. pneumoniae were repor-
ted in a survey of 13 Korean hospitals in 2002.3 GES-type ESBLs
are within the Ambler class A but have different substrate
specificity. GES-1, which was detected inK. pneumoniae in French
Guiana, had activity against cefoxitin, whereas GES-2 from
Pseudomonas aeruginosa in South Africa was active against
imipenem.4 Recently, a few derivatives of GES-type ESBLs
have been isolated in Greece and Japan.5,6
The aim of the present study was to describe the prevalence and
shift of the ESBLs including non-TEM or -SHV ESBLs in E. coli
and K. pneumoniae in recent years in Korea.
Methods
Bacterial strains
Consecutive non-duplicate nosocomial isolates of E. coli (n = 246)
and K. pneumoniae (n = 239) were collected during February–July
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2003 from 12 hospitals in Korea (Figure 1). E. coli J53 AzideR was
used as the recipient strain for conjugation. E. coli ATCC 25933 was
used as the reference strain for antimicrobial susceptibility testing.
Antimicrobial susceptibility tests and b-lactam resistance
transfer assays
Antimicrobial susceptibilities were determined by disc diffusion and
agar dilution methods according to the recommendations of the
NCCLS.7,8 ESBL production was detected by the double-disc synergy
(DDS) method. Mating experiments were performed as described
previously.1 Transconjugants were selected on MacConkey agar
supplemented with ceftazidime (2 mg/L) and sodium azide
(150 mg/L; Sigma, St Louis, MO, USA).
Isoelectric focusing
Crude bacterial extracts from clinical isolates were prepared as
described previously.1 Sonic extracts and sample buffer (TEFCO cor-
poration, Tokyo, Japan) were mixed in equal amounts and separated by
electrophoresis on precast polyacrylamide gels (pH 3–10, TEFCO
corporation, Tokyo, Japan) for 1 h at 100 V, 1 h at 200 V and
40 min at 300 V. b-Lactamase activity was detected with 0.5 mM
nitrocefin (Oxoid, Basingstoke, UK).
Molecular analysis
Primers used in this study are listed in Table 1. The templates for PCR
amplification in clinical isolates were a whole-cell lysate or a plasmid
preparation. The PCR products were then subjected to direct sequen-
cing. Both strands of each PCR product were sequenced twice with an
automatic sequencer (model 373A; Applied Biosystems, Weiterstadt,
Germany).
Results
In the study period, clinical isolates of E. coli (n = 246) and
K. pneumoniae (n = 239) were obtained from outpatients (43.1
and 23.0%, respectively), inpatients of general wards (46.3 and
60.7%, respectively) and inpatients of intensive care units (ICUs)
(10.6 and 16.3%, respectively). They were from urine (52.6%),
wound (18.2%), sputum (17.1%), blood (8.2%) and body fluid
(3.9%). ESBL production was detected in 9.3% (23/246) of
E. coli and 23.0% (55/239) of K. pneumoniae by the DDS test.
DDS-positive isolates were found in all 12 hospitals (Figure 1). The
greatest numbers of ESBL-producing isolates were found in a
hospital in Suwon city (E. coli, 5/20; K. pneumoniae, 9/20). The
DDS-positive rates were higher in isolates from ICUs (E. coli,
23.1%; K. pneumoniae, 35.9%) than from outpatients or inpatients
of general wards (E. coli, 0.9% and 14.0%; K. pneumoniae, 0.9%
and 24.8%, respectively). Transfer of ceftazidime resistance to the
E. coli J53 AzideR recipient by conjugation was successful for
only 11 of 23 DDS-positive E. coli and 33 of 55 DDS-positive
K. pneumoniae isolates.
Among 23 and 55 DDS-positive E. coli and K. pneumoniae
isolates, genes encoding TEM-type b-lactamases were detected
in 78.3% (18/23) of E. coli and 60% (33/55) of K. pneumoniae.
Most of them were TEM-1 except for one isolate each of E. coli
and K. pneumoniae that had TEM-52. The most common types
of class A ESBLs identified were SHV-12 and CTX-M-3 in
K. pneumoniae, and CTX-M-15 and CTX-M-3 in E. coli. GES-
3, which was detected for the first time in Korea, was detected in
two isolates of K. pneumoniae from Bundang city. Six isolates
(12.2%) of K. pneumoniae and one E. coli carried multiple ESBL
genes (Table 2). Non-TEM- and non-SHV-type ESBLs including
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Figure 1. Location ofKorean hospitals involved in this surveywith the numbers of double-disc synergy-positive (DDS+) isolates and distribution of Ambler class A
ESBLs at each hospital in parentheses.
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PER-1, VEB, IBC and TLA-type ESBLs and members of CTX-M-
2 and -8 groups were not detected in this survey. For 14 of 23
(60.9%) DDS-positive E. coli and six of 55 (10.9%) DDS-positive
K. pneumoniae isolates no ESBL was detected. These isolates may
have produced another ESBL, which was not determined in this
study or might have given positive results for ESBL activity.
All of the 31 isolates producing SHV-12 were resistant to
ceftazidime (MIC ‡ 64 mg/L). Five isolates producing both
SHV-12 and CTX-M-type ESBLs were highly resistant to both
ceftazidime and cefotaxime (both MICs ‡ 256 mg/L). Four isolates
producing only CTX-M-14 hadmore than fourfold higherMICs for
cefotaxime than for ceftazidime, but the isolates producing CTX-
M-15 had similar levels of MICs for these drugs except one. Two
isolates producing both GES-3 and SHV-12 had higher MICs for
ceftazidime (‡256 mg/L) than for cefotaxime (64 mg/L). In
isoelectric focusing studies, each of SHV-5, SHV-12, TEM-52,
CTX-M-3, CTX-M-14, CTX-M-15 and GES-3 enzymes had cor-
responding pIs at 7.6, 8.2, 6.0, 8.4, 8.1, 8.6, and 6.1, respectively.
Discussion
Compared with a survey in 1997,9 the prevalence of ESBL-
producing E. coli and K. pneumoniae has increased from 4.8 to
9.3% and 22 to 23%, respectively, in Korea. Past reports showed
that the most common ESBL in Korea was TEM-52,9 but it was
detected in only one isolate each of E. coli and K. pneumoniae in
this study. In 1998, about 70% (27/39) of K. pneumoniae isolates
that produced SHV-type ESBLs were SHV-12, which confers
higher levels of resistance against ceftazidime than SHV-2a and
SHV-5, and the remaining 30% carried SHV-2a.10 However,
86% (31/36) of SHV-type ESBLs were SHV-12 and only 8%
(n = 3) and 6% (n = 2) were SHV-2a and SHV-5, respectively
in this study.
We have previously shown that only 1.7% (9/520) of clinical
E. coli and K. pneumoniae isolates produced CTX-M-type ESBLs
in 2002,3 but the prevalence of these enzymes was increased to
4.4% (26/585) in the present study. CTX-M-3 was the most com-
mon enzyme among CTX-M-type ESBLs, and was isolated from
five hospitals (Figure 1). CTX-M-15 differs from CTX-M-3 by
one amino acid substitution from glycine to aspartate at position
240, and this amino acid change results in increased enzymatic
activity against ceftazidime.2 It was also observed in this study that
MICs of ceftazidime for four isolates of E. coli that produced
CTX-M-15 were all ‡128 mg/L, which was higher than that of iso-
lates producing other CTX-M-type ESBLs. Another noteworthy
finding was that five CTX-M-type ESBL-producing isolates also
produced SHV-12, simultaneously, and they were highly resistant to
both ceftazidime and cefotaxime. Simultaneous production of both
cefotaximase and ceftazidimase may confer a higher level of res-
istance against these oxyimino-cephalosporins in clinical isolates.
GES-3 was originally found in an E. coli isolate from a hospital
in Greece.5 GES-type ESBLs have not been reported before in
Korea. However, in the present study, we found that two isolates
of K. pneumoniae from a hospital in Bundang city produced both
GES-3 and SHV-12 ESBLs. The MIC of ceftazidime (MIC ‡
256 mg/L) was more than fourfold higher than that of cefotaxime
(MIC 64 mg/L) in both of these isolates, and showed little change
when clavulanic acid was added.
The present data suggest that the incidence of isolation of
SHV-12 and CTX-M-type ESBLs has increased in E. coli and
K. pneumoniae isolates in Korea. In conclusion, 9.3% of E. coli
and 23.0% of K. pneumoniae isolates from Korea have produced
Ambler class A ESBLs. The most common ESBLs in E. coli
isolates were CTX-M-15 and CTX-M-3, and in K. pneumoniae
were SHV-12 and CTX-M-3. In addition, a GES-type ESBL has
emerged in Korea.
Table 1. Sequences of the primers used to detect Ambler class A b-lactamase genes
Primer name Oligonucleotide sequence PCR target Product size (bp)
TEM-F 50-ATG AGT ATT CAA CAT TTC CGT-30 blaTEM 861
TEM-R 50-TTA CCA ATG CTT AAT CAG TGA-30
SHV-F 50-CCG GGT TAT TCT TAT TTG TCG CT-30 blaSHV 831
SHV-R 50-TAG CGT TGC CAG TGC TCG-30
C1-F 50-GGA CGT ACA GCA AAA ACT TGC-30 blaCTX-M (CTX-M-1 group) 624
C1-R 50-CGG TTC GCT TTC ACT TTT CTT-30
C2-F 50-CGG TGC TTA AAC AGA GCG AG-30 blaCTX-M (CTX-M-2 group) 891
C2-R 50-CCA TGA ATA AGC AGC TGA TTG CCC-30
C8-F 50-ACG CTC AAC ACC GCG ATC-30 blaCTX-M (CTX-M-8 group) 490
C8-R 50-CGT GGG TTC TCG GGG ATA A-30
C9-F 50-GAT TGA CCG TAT TGG GAG TTT-30 blaCTX-M (CTX-M-9 group) 947
C9-R 50-CGG CTG GGT AAA ATA GGT CA-30
PER-1-F 50-GTT AAT TTG GGC TTA GGG CAG-30 blaPER-1 855
PER-1-R 50-CAG CGC AAT CCC CAC TGT-30
VEB-F 50-ACC AGA TAG GAG TAC AGA CAT ATG A-30 blaVEB 727
VEB-R 50-TTC ATC ACC GCG ATA AAG CAC-30
I/G-F 50-GTT AGA CGG GCG TAC AAA GAT AAT-30 blaIBC and blaGES 903
I/G-R 50-TGT CCG TGC TCA GGA TGA GT-30
TLA-F 50-CGC GAA AAT TCT GAA ATG AC-30 blaTLA 992
TLA-R 50-AGG AAA TTG TAC CGA GAC CCT-30
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